Clinical Trial Details

NCT ID: NCT00908778
Date Last Changed: October 19, 2009


Research Study Summary

A clinical trial seeking patients for a research study for the treatment of Diabetic Retinopathy

Research Study Title

A Phase 3 Safety and Efficacy Study of Vitreosolve® for Four Ophthalmic Intravitreal Injections For Inducing Posterior Vitreous Detachment in Retinopathy Patients.


The purpose of this study is to determine the safety and efficacy of Vitreosolve® in diabetic retinopathy patients.

To Learn more

Recruitment Details

Both Male and Female
50 and up
Overall Status
Lead Sponsor
Vitreoretinal Technologies, Inc.
21 Months
Facility Type


Both Male and Female ages 50 Years and up

Inclusion Criteria:

  • Subjects with a history of systemic diabetes(type I,or II)

  • Subject with a documented history of Non- proliferative Diabetic Retinopathy(NPDR)

  • Subjects with no or partial PVD at baseline exam in study eye.

Exclusion Criteria:

  • Subjects with retinal pathology in the study eye other then (NPDR)

  • Subjects with high myopia in the study eye

  • Subjects who have monocular vision or central lateral vision of 20/200 or worse BCVA in the non-study eye.

  • Subjects with an aphakic study eye or if pseudophakic, cataract extraction surgery less then 6 months prior to study enrollment.

  • Subjects that have either vitrectomy surgery, intavitreal injections, or laser treatments in the study eye.

Site Locations (5)

Country State City Zip Facility and Contact
India AP Vizag LVPEI
India Kochi Amrita
Mexico Coyoacan San Lucas La Ceguera
Mexico DF Mexico City Conde De Valenciana
Mexico Neuvo Leon Monterrey Hidalgo


Philip N Calvillo
949-753-1008 ext. 120

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.